Short report

HLA antigens and myasthenia gravis in north India

NK MEHRA,* GK AHUJA,† V TANEJA,* MC VAIDYA*

From the Department of Anatomy* (Cellular Immunology Laboratory) and Department of Neurology,† All India Institute of Medical Sciences, New Delhi, India

SUMMARY The HLA antigen distribution was studied in 37 north Indian patients with myasthenia gravis. The control group consisted of 118 normal, healthy individuals of the same ethnic group. The antigens showing the highest frequency were Bw21 (18.9% vs 4.2% $p < 0.005$), Bw35 (24.3% vs 6.8%, $p < 0.005$) and A9 (51.3% vs 30.5%, $p < 0.025$). HLA-B8 was increased nearly two fold in the myasthenia gravis patients ($RR = 2.4$) and was confined mainly to the young females without thymoma. The possibility that Bw21 and Bw35 might be the markers for susceptibility to autoimmune disorders in India is discussed. The observations also support those of others that HLA-B8 linked susceptibility gene is more frequently found in myasthenia gravis patients with thymic hyperplasia.

Epidemiological observations on myasthenia gravis have indicated the familial nature of this disease.¹ However, the pattern of inheritance and the pathogenetic significance of the autoantibodies in myasthenic patients are not clear. Several groups have tried to establish the association of myasthenia gravis with HLA antigens. Most of these investigations have been done in individuals of Caucasian origin. A constant finding has been the increased frequency of HLA-B8 antigen particularly in the young females.²⁻⁵ Others, while confirming the association of B8 in female patients, reported the association of HLA-A3 or HLA-A2 in male patients with thymoma or with late onset of disease.^{6,7} Both these groups of workers, however, reported decrease of HLA-B7 in myasthenia gravis. This led investigators to believe that there might be two forms of the disease and that their inheritance may be under polygenic control. There is as yet no data available on HLA and myasthenia gravis in Indian patients. This along with our own findings on the association of HLA-Bw21 and Bw35, rather than B8 in patients of insulin-dependent diabetes mellitus⁸ prompted us to undertake HLA studies in

myasthenia gravis patients. The known race specificity of the HLA and disease association provided further impetus for such studies.

Material and methods

Thirty seven unrelated north Indian patients with myasthenia gravis attending the Neurology clinic of the All India Institute of Medical Sciences Hospital, New Delhi were selected for the study. Ethnically, they represented north Indian Hindus belonging to the states of Punjab, Haryana, Uttar Pradesh and Delhi. The diagnosis of myasthenia gravis was made on compatible clinical picture and was confirmed by unequivocal response to prostigmin test. The diagnosis was further supported by decremental response to repeated nerve stimulation and stapedius reflex.⁹ All patients had radiographs of the chest, with postero-anterior and lateral views taken for evidence of thymoma. Chest tomography was done whenever the plain radiographs revealed equivocal evidence of thymoma. All patients with thymoma were subjected to thymectomy and the diagnosis verified histologically.

The control group for comparison consisted of 118 unrelated healthy persons of the same racial and ethnic background. HLA typing for the detection of antigens in the HLA-A and B loci was performed using the two stage NIH microlymphocytotoxicity test with slight modifications.¹⁰ The antisera for typing were supplied by the kind courtesy of Prof Jon Van Rood, Eurotransplant Foundation, Leiden and the NIH serum bank, USA.

Relative risk (RR) for a particular antigen was calculated by the formula

$$RR = \frac{a \times d}{b \times c}$$

Address for reprint requests: Dr GK Ahuja, Associate Professor of Neurology, All India Institute of Medical Sciences, New Delhi-110029, India.

Received 30 April 1982 and in revised form 8 October 1982.
Accepted 20 November 1982

where a and b are the number of patients with or without the antigen respectively, and c and d are the corresponding numbers of controls. The percent phenotype frequencies of antigens in patients and controls were compared on a 2×2 table using Yates' correction.

Results

Table 1 shows the percent HLA antigen frequencies in patients and controls along with the relative risk for each antigen. The frequency of HLA-Bw21, Bw35 and A9 was significantly increased in the patient group as against the controls. Bw21 presented the highest relative risk of 5.0 in our series of patients. HLA-B8 was increased nearly two fold in the myasthenia gravis patients (RR = 2.4) but did not reach statistical significance. Antigen HLA-B7

was present with a decreased frequency in the patient group (8.1%) as compared to the controls (22.9%), ($\chi^2 = 3.93$, $p = 0.05$). HLA-A2 and A3 did not demonstrate any significant deviation in myasthenia gravis patients as compared to controls.

Striking differences were observed when the thymoma and the non-thymoma group of patients were analysed separately for their HLA antigen distribution (table 2). Only HLA-Bw35 was raised in both the groups. There was a strong association with HLA-B8 and Bw21 in only those patients who did not have thymoma. Antigen B8 was present in eight out of the 25 patients in this group (frequency 32%). This is statistically significant when compared to the B8 frequency of 11.9% in the controls. Seven out of these eight patients were females with onset of disease below 30 years. In the thymoma group,

Table 1 Percent HLA antigen frequencies in patients with myasthenia gravis in north India: A and B loci

HLA specificity	Patients (N = 37)		Controls (N = 118)		Relative risk	p value
	Number	%	Number	%		
HLA-A1	7	18.9	31	26.3	0.65	<0.025
A2	9	24.3	33	28.0	0.82	
A3	6	16.2	25	21.2	0.72	
A9	19	51.3	36	30.5	2.40	
A10	8	21.6	18	15.3	1.50	
A11	11	29.7	22	18.6	1.85	
A28	5	13.5	17	14.4	0.92	
A29	4	10.8	13	11.0	0.98	
Aw30	2	5.4	4	3.4	1.62	
Aw31	2	5.4	3	2.5	2.10	
Aw32	1	2.7	9	7.6	0.34	
Aw33	0	0.0	1	0.8	—	<0.05
B5	15	40.5	34	28.8	1.68	
B7	3	8.1	27	22.9	0.29	
B8	9	24.3	14	11.9	2.40	
B12	5	13.5	25	21.2	0.58	
B13	0	0.0	16	13.6	—	
B14	0	0.0	0	0.0	—	
B15	6	16.2	20	17.0	0.94	
Bw16	2	5.4	0	0.0	—	
B17	9	24.3	27	22.8	1.0	
B18	1	2.7	5	4.2	0.63	<0.005
Bw21	7	18.9	5	4.2	5.00	
Bw22	3	8.1	4	3.4	2.51	
B27	1	2.7	7	5.9	0.44	
Bw35	9	24.3	8	6.8	4.00	
B37	1	2.7	3	2.5	1.06	
B40	4	10.8	26	22.0	0.43	

Table 2 Percent HLA antigen frequencies in thymoma and non-thymoma group of patients

HLA antigen	Controls (118)	Thymoma (12)		Non-thymoma (25)	
		Freq	p value	Freq	p value
HLA-A9	30.5	75.0	$p < 0.005$	40.0	NS
B7	22.9	8.3	NS	8.0	NS
B8	11.9	8.3	NS	32.0	$p < 0.025$
B15	17.0	16.7	NS	16.0	NS
Bw21	4.2	16.7	NS	20.0	$p < 0.005$
Bw35	6.8	25.0	$p < 0.05$	24.0	$p < 0.01$

NS = not significant.

HLA-A9 showed the highest phenotype frequency of 75% as compared to 30.5% in the control group. Both B8 as well as Bw21 did not show any association in this group. The only B8 positive patient with thymoma was a female in whom the first symptoms of myasthenia were observed at the age of 40 years.

Discussion

The association of HLA-B8 in Caucasian female patients with an early onset of myasthenia gravis is well established.⁵ This study which is the first report on the HLA antigen distribution in north Indian patients with myasthenia gravis indicates that it is strongly associated with HLA-Bw21 (19% vs 4%, RR = 5) and Bw35 (24% vs 7%, RR = 4), HLA-B8 was increased nearly two fold (RR = 2.4) but did not reach statistical significance. This association of Bw21 and Bw35 with myasthenia gravis seems to be specific to the Indian population since the frequency of these antigens in the normal population does not differ significantly in Indians in comparison with Caucasians.¹¹ In a recent study of the Japanese myasthenics, Yoshida *et al*¹² reported an increased incidence of HLA-B12 especially in young females with early disease and thymic hyperplasia. These studies, therefore, emphasise the race specificity of the HLA and disease associations.

Besides myasthenia gravis, HLA-B8 has been reported to be associated with many other autoimmune disorders in Caucasians such as diabetes mellitus, thyrotoxicosis, Addison's disease, coeliac disease.¹³ Our earlier studies on Insulin-dependent diabetes mellitus (Type I) conducted on patients of north Indian origin revealed an association with Bw21 and Bw35 rather than with B8.⁸ It is possible that in a population like the one under consideration, Bw21 and Bw35 can apparently play the same role as genetic marker as B8 in Caucasians at least so far as the autoimmune disorders are concerned. The similarity in the negative association with HLA-B7 in Caucasians and north Indians indicates that the B-allele conferring protection in myasthenia gravis might be common in several populations.

The observed increased frequency of B8 in the non-thymoma group of patients particularly the females with an early onset of the disease support the hypothesis that the B8 linked susceptibility gene is more frequently found among myasthenia gravis patients with thymic hyperplasia and is related to the early age of onset. Whether this has any influence of the sex-linked factors is not certain since studies exclusively on male myasthenia gravis patients have suggested that the association with B8 is equally strong in males particularly those with age of onset below 35 years.¹⁴

The increased frequency of A9 in north Indian myasthenia gravis patients with thymoma is quite striking. It is of interest that others have reported an excess of A2 and A3 in their patients with thymoma.^{6,7} These observations suggest that other MHC-linked genetic factors play a key role in susceptibility to myasthenia gravis. Moreover, family studies by Dick *et al*³ have demonstrated amply that B8 is not an essential pre-requisite for the development of the disease and that B8 homozygosity does not in any way enhance the risk of developing myasthenia gravis. It appears, therefore, that though B8 or other B-locus antigens (Bw21 and Bw35 in north Indians) clearly increase one's susceptibility to develop myasthenia gravis, other factors including environmental play a significant role. It is thus logical to conclude that myasthenia gravis occurs as a result of an interaction between multiple host genetic and environmental influences.

The authors thank Prof. Jon van Rood, Leiden and the NIH serum Bank, USA for the supply of HLA antisera. The study was supported by grants from the Indian Council of Medical Research (ICMR), New Delhi.

References

- Kurland LT, Alter M. Current status of the epidemiology and genetics of myasthenia gravis. In: Viets HR, ed. *Myasthenia Gravis*. Springfield: Thomas, 1961:307-36.
- Safwenberg J, Lindblom JB, Osterman PO. HLA frequencies in patients with myasthenia gravis. *Tissue Antigens* 1973;3:465-9.
- Dick HM, Behan PO, Simpson JA, Durward WF. The inheritance of HLA antigens in myasthenia gravis. *J Immunogenet* 1974;1:401-12.
- Pirakanen R. Genetic association between myasthenia gravis and the HL-A system. *J Neurol Neurosurg Psychiatry* 1976;39:23-33.
- Behan PO. Immune disease and HLA associations with myasthenia gravis. *J Neurol Neurosurg Psychiatry* 1980;43:611-21.
- Fritz D, Herman C Jr, Naeim F, Smith GS, Walford RL. HLA antigens in myasthenia gravis. *Lancet* 1974;1:240-43.
- Feltkamp TW, van den Berg-Loonen PH, Nijenhuis LE, *et al*. Myasthenia gravis, autoantibodies and HLA antigens. *Br Med J* 1974;1:131-3.
- Srikantha S, Mehra NK, Vaidya MC, Malviya AN, Ahuja MMS. HLA antigens in type I (insulin-dependent) diabetes mellitus in north India. *Metabolism* 1981;30:992-3.
- Ahuja GK, Verma A, Ghosh P, Nagaraj MN. Stepped reflexometry. A diagnostic test of myasthenia gravis. *J Neurol Sci* 1980;46:311-4.

- ¹⁰ Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. *Nature* 1964;**204**:998–1000.
- ¹¹ Nerup J, Cathelineau Cr, Seignalet J, Thomsen M. HLA and endocrine disease. In: Deusset J, Svejgaard A, eds. *HLA and disease*. Copenhagen: Munksgaard, 1977:149–67.
- ¹² Yoshida T, Tsuchiya M, Ono A, Yoshimatsu H, Satoyoshi E, Tsuji K. HLA antigens and myasthenia gravis in Japan. *J Neurol Sci* 1977;**32**:195–201.
- ¹³ Eddleston ALWF, Williams R. HLA and liver disease. *Br Med Bull* 1978;**34**:295–300.
- ¹⁴ Safwenberg J, Hammerstrom L, Lindblom JB, et al. HLA-A, -B, -C and -D antigens in male patients with myasthenia gravis. *Tissue Antigens* 1978;**12**:136–42.